Request Demo

Last update 03 Nov 2025

Fentanyl Citrate

Last update 03 Nov 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Abstral Sublingual, E-Fen Buccal, Fentanyl citrate (JP17/USP)

+ [33]

Target

μ opioid receptor

Action

agonists

Mechanism

μ opioid receptor agonists(Mu opioid receptor agonists)

Therapeutic Areas

Nervous System DiseasesUrogenital DiseasesOther Diseases

Active Indication

Breakthrough PainCancer PainHyperemesis Gravidarum+ [1]

Inactive Indication

Anemia, Sickle CellBurnsChronic Pain+ [9]

Originator Organization

Rising Pharmaceuticals, Inc.

Active Organization

Grünenthal GmbH

Kyowa Kirin Co., Ltd.

Istituto Gentili Srl

+ [5]

Inactive Organization

Kyowa Kirin Services Ltd.Teva Branded Pharmaceutical Products R&D, Inc.

Cephalon, Inc.

+ [6]

License Organization

Kunwha Pharmaceutical Co., Ltd.

Daiichi Sankyo Co., Ltd.

Collegium Pharmaceutical, Inc.

+ [7]

Drug Highest PhaseApproved

First Approval Date

United States (19 Feb 1968),

Anesthesia

Regulation-

Structure/Sequence

Molecular FormulaC28H36N2O8

InChIKeyIVLVTNPOHDFFCJ-UHFFFAOYSA-N

CAS Registry990-73-8

1,089

Clinical Trials associated with Fentanyl Citrate

NCT07214714

/ Not yet recruitingPhase 4IIT

Hemodynamic and Cardiac Effects of Dexmedetomidine Versus Fentanyl by Intravenous Infusion as Adjuncts to General Anesthesia in Patients Undergoing Major Abdominal Cancer Surgeries.

________________________________________
Background :
Major abdominal cancer surgery is among the most invasive procedures, often associated with extensive tissue damage, severe postoperative pain, and delayed recovery. Inadequate pain management can result in adverse physiological responses such as tachycardia, hypertension, prolonged immobility, and extended hospital stay. Moreover, poorly controlled pain may impair immune function and contribute to neuroendocrine, metabolic, gastrointestinal, and cardiopulmonary complications. Therefore, effective analgesia is essential to improve patient outcomes and recovery.
Multimodal analgesia has emerged as the gold standard for managing postoperative pain in major abdominal surgery. It integrates regional techniques (such as epidural or intrathecal analgesia), peripheral nerve blocks (e.g., transversus abdominis plane block), systemic opioids, and non-opioid agents including NSAIDs and acetaminophen. This approach minimizes surgical stress, maintains hemodynamic stability, and facilitates early ambulation and discharge.
Opioids, particularly fentanyl, are widely used as intrathecal adjuvants due to their rapid onset and favorable analgesic profile. However, selective alpha-2 adrenergic receptor agonists such as clonidine and dexmedetomidine are gaining attention for their sedative, analgesic, sympatholytic, and hemodynamic-stabilizing effects. Administered intrathecally, epidurally, or intravenously, they can enhance analgesia while reducing anesthetic requirements without causing profound sedation.
Conventional monitoring with heart rate and non-invasive blood pressure may overlook subtle variations in cardiac output. Electrical cardiometry (ICON®) provides continuous, non-invasive, beat-to-beat measurement of cardiac parameters and has been validated across different patient groups. Accordingly, the present study aims to compare intravenous dexmedetomidine and fentanyl as adjuvants to general anesthesia, focusing on their effects on hemodynamics and cardiac function in major abdominal cancer surgery using electrical cardiometry.

Start Date01 Nov 2025

Sponsor / Collaborator

Assiut University

NCT07091123

/ RecruitingPhase 4IIT

Patient Preference and Long-term Outcomes in Persistent Spinal Pain Syndrome: A Prospective Study Comparing Spinal Cord Stimulation to Intrathecal Drug Delivery.

Spinal cord stimulation (SCS) or intrathecal drug delivery (pain pump) can be effective in providing pain relief for patients with low back pain who have not responded to other treatments. While both treatments, SCS and pain pump, may help with low back pain relief, it is not known which treatment may work better for patients. SCS and pain pumps involve an implanted device in the body.
In this study, we are asking patients to undergo a trial of both treatment modalities, SCS and pain pump, as screening tests prior to considering an implant. A total of 36 patients will be enrolled in this study. After both trials are completed, participants will be seen in the office and asked which treatment modality they believe has been more effective for relieving pain during the trial periods by completing questionnaires. If neither treatment was effective in improving baseline pain by at least 50%, participants would not qualify for either implant whether or not they are part of this study. Direct study participation would end here. If either or both treatment modalities improved baseline pain by at least 50%, participants will be asked to choose the treatment that worked better: SCS or pain pump. Participants will then have the option to proceed to the permanent implant of choice: SCS or pain pump. Direct study participation would end here but participants will then be followed in the doctor's office after implant as is customary for usual clinical care. The study data collection will conclude when the screening tests are completed.

Start Date13 Oct 2025

Sponsor / Collaborator

University Hospitals Cleveland Medical Center

NCT07112430

/ Not yet recruitingPhase 1/2IIT

Intranasal Fentanyl to Reduce Pain Intensity Associated With Retinopathy of Prematurity Screening in Preterm Infants: A Randomized Control Trial

This single-center, double-blinded, randomized controlled trial aims to evaluate the efficacy and safety of intranasal fentanyl (INF) for reducing pain during retinopathy of prematurity (ROP) screening in preterm infants. The trial will enroll preterm neonates (≤32 weeks gestation) requiring ROP screening and randomize them to receive either intranasal fentanyl (2 mcg/kg) or a placebo (normal saline) 5-10 minutes prior to the procedure. The primary outcome is pain intensity measured using the Premature Infant Pain Profile-Revised (PIPP-R) at 30 seconds after speculum insertion. Secondary outcomes include physiological (heart rate, oxygen saturation), behavioral (crying time), and recovery indicators, along with adverse events and need for rescue dosing. This study addresses a critical gap in evidence by exploring a non-invasive pharmacologic intervention for procedural pain in the neonatal intensive care unit (NICU) setting. The findings may inform future practice and guidelines for neonatal pain management.

Start Date01 Oct 2025

Sponsor / Collaborator

IWK Health Centre

[+1]

100 Clinical Results associated with Fentanyl Citrate

100 Translational Medicine associated with Fentanyl Citrate

100 Patents (Medical) associated with Fentanyl Citrate

8,587

Literatures (Medical) associated with Fentanyl Citrate

01 Nov 2025·BRITISH JOURNAL OF ANAESTHESIA

Impact of neuromuscular block monitoring and reversal on postoperative pulmonary complications in thoracic surgery: a Bayesian analysis of the iPROVE-OLV trial

Article

BACKGROUND:

Postoperative pulmonary complications (PPCs) are a significant concern in thoracic surgery. A modifiable factor influencing PPCs is postoperative residual neuromuscular block (NMB), which impairs respiratory muscle function.

METHODS:

We performed a post hoc Bayesian analysis of data from the iPROVE-OLV study, a multicentre randomised controlled trial involving patients undergoing thoracic surgery with one-lung ventilation. We compared participants managed with any neuromuscular monitoring and any reversal vs those managed without either. The primary outcome was the occurrence of a composite of PPCs within the first 7 postoperative days.

RESULTS:

Of the 698 patients included, 657 received any neuromuscular monitoring and any reversal, while 41 did not. Patients managed with any neuromuscular monitoring and any reversal had a lower incidence of PPCs (20%) compared with those without either (34%). Bayesian random effect logistic regression indicated that the use of any neuromuscular monitoring and any reversal reduced PPCs with an odds ratio (OR) ranging from 0.67 (95% credibility interval, CrI, 0.39-1.11) to 0.84 (95% CrI 0.48-1.37), depending on the prior model used. The probability of benefit (OR <1) was between 77% and 94%. Subgroup analysis indicated that sugammadex was more effective than neostigmine in reducing PPCs, with a high probability of benefit (97%), and both neuromuscular monitoring and reversal reduced PCCs when evaluated separately with a high probability of benefit.

CONCLUSION:

Utilising neuromuscular monitoring and reversal agents significantly reduced the risk of PPCs in thoracic surgery. Sugammadex was more efficacious in reducing PPCs compared with neostigmine. These findings support the combined use of neuromuscular monitoring and reversal drugs.

CLINICAL TRIAL REGISTRATION:

NCT03182062.

01 Nov 2025·SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY

A novel label-free carbon dots-based fluorescent aptamer sensor for the detection of fentanyl

Article

Author: Tong, Yishuo ; Yan, Jiangwei ; Niu, Weifen ; Wang, Zheyu ; Liu, Baihui ; Dong, Chuan

Fentanyl, a widely abused potent synthetic opioid, poses a challenge due to its narrow therapeutic window, increasing the risk of overdose and death. Fast, easy, and cost-effective screening for fentanyl in biological samples is crucial for forensic and public safety purposes. We hereby present a label-free fluorescence sensor for the precise and sensitive identification of fentanyl, utilizing carbon dots (CDs) in conjunction with aptamers. By synthesizing green-emitting CDs in a single step using an environmentally friendly method with o-phenylenediamine (OPD) and thiourea in acetone, the CDs displayed excellent optical properties and biocompatibility. Due to the positive charge of CDs, their fluorescence quenching is caused by electrostatic interactions with negatively charged aptamers. When fentanyl is introduced, the specific binding between fentanyl and the fentanyl aptamer is strengthened, resulting in fluorescence recovery. Under optimal experimental conditions, there was a linear relationship between fluorescence intensity and fentanyl concentration in the 5-1000 nM with a limit of determination of 1.90 nM. The robust quantification of fentanyl in complex human saliva matrices achieved by this aptamer-based biosensing platform validates its clinical reliability, particularly for non-invasive point-of-care monitoring and harm-reduction interventions in opioid crisis management.

03 Oct 2025·The International journal of neuroscience

The effects of combined acupuncture anesthesia and serratus anterior plane block with ropivacaine on postoperative analgesia in patients undergoing chest surgery

Article

Author: Wu, Zhen ; Wang, Jieqiong ; Wang, Chunfeng ; Shi, Lingyan ; Yu, Xiangyuan ; Cai, Hongqin

OBJECTIVE:

To investigate the effects of combined acupuncture anesthesia and ropivacaine on postoperative analgesia and neuro-related factors in patients undergoing chest surgery.

METHODS:

The analgesic drug dosage, postoperative PCIA pressing times, VAS scores at rest and during activity at 6 h (T1), 12 h (T2), 18 h (T3), and 24 h (T4) postoperatively.

RESULTS:

The analgesic drug dosage and postoperative PCIA pressing times were lower in the observation group than in the control group (p < 0.05). The VAS scores at T1-T4 postoperatively were lower in the observation group than in the control group (p < 0.05). The SAS scores at T1-T4 postoperatively were lower in the observation group than in the control group (p < 0.05). The levels of IL-6 and IL-10 on postoperative day 1 were higher than those on preoperative day 1 in both groups, with a smaller change in the observation group (p < 0.05). The levels of S100β protein on postoperative day 1 were higher than those on preoperative day 1 in both groups, while the BDNF levels were lower, with a smaller change in the observation group (p < 0.05). There was no significant difference in the incidence of adverse reactions between the control group (11.36%) and the observation group (15.56%) (p > 0.05).

CONCLUSION:

Combined acupuncture anesthesia and ropivacaine can effectively improve postoperative analgesia and agitation in patients undergoing chest surgery, reduce the dosage of analgesic drugs, regulate the levels of inflammatory factors and neurotrophic factors in patients, and do not increase the risk of adverse reactions related to patients.

News (Medical) associated with Fentanyl Citrate

29 Oct 2025

·www.prnewswire.com

CounterX Therapeutics Announces Publication Demonstrating CTRX-101, an Anti-Fentanyl Monoclonal Antibody Therapy, Reverses Fentanyl-Induced Overdose in Preclinical Model

SEATTLE, Oct. 29, 2025 /PRNewswire/ -- CounterX Therapeutics, Inc., a biotechnology company focused on developing novel antibody therapeutics and vaccines to address opioid overdose and dependence, today announced the publication of its latest peer-reviewed preclinical study in The Journal of Pharmacology and Experimental Therapeutics. The study highlights the potential of CTRX-101, CounterX Therapeutics' proprietary anti-fentanyl monoclonal antibody, to rapidly reverse life-threatening respiratory depression caused by exposure to fentanyl and its analogs. Conducted in a translational preclinical model, the study demonstrates that administration of the CTRX-101 effectively restores normal breathing following fentanyl overdose. Fentanyl overdose is the leading cause of death for Americans aged 18 – 45. Fentanyl overdoses result in approximately 50,000 deaths and more than 700,000 emergency department visits each year. CTRX-101 is being developed for the prevention and treatment of fentanyl overdose in patients with moderate to severe opioid use disorder (OUD). "These findings provide strong supporting evidence for the clinical development of CTRX-101 to address lethal overdoses with fentanyl," said Dr. Marco Pravetoni, Founder and Chief Scientific Officer at CounterX Therapeutics. "Unlike existing therapies that rely on opioid receptor blockade, CTRX-101 binds to fentanyl, sequesters it in the bloodstream, and prevents its lethal effects on the brain and respiratory system." The publication reinforces CounterX Therapeutics' leadership in developing novel therapies and builds on previous preclinical studies of CTRX-101 that demonstrate efficacy, selectivity, and safety for the prevention and treatment of acute fentanyl overdose. "This exciting study marks a key milestone in translating products developed with our CounterXL™ Platform from preclinical models to potential human application," said Dr. Shawn Iadonato, Chief Executive Officer at CounterX Therapeutics. "We believe CTRX-101 has the potential to provide a differentiated pre-exposure prophylaxis treatment for fentanyl and complement current standards of care in opioid use disorders." The full article is available for viewing under Publications section of the company's website at . About CounterX Therapeutics CounterX Therapeutics is at the forefront of the battle against the opioid epidemic, exploiting cutting-edge biotechnology to develop life-saving therapeutics and vaccines. We combine scientific expertise with an experienced leadership team and a deep commitment to social impact. Our groundbreaking antibody therapies are designed to blunt the effects of opioids, reduce the risk of overdose and a provide a path to recovery. Additionally, our pioneering vaccine technology aims to prevent addiction relapse by blocking the euphoric effects of opioids, empowering individuals to maintain a long-term recovery. Dr. Marco Pravetoni is the Founder and Chief Scientific Officer at CounterX Therapeutics and Professor of Psychiatry and Behavioral Sciences at the University of Washington School of Medicine. CTRX-101: CTRX-101, is a monoclonal antibody against fentanyl that is in development for the prevention of accidental overdose in high-risk patients. It is a long-acting subcutaneous injectable product that is not an opioid or controlled substance. CTRX-101 was well-tolerated in preclinical models with no serious adverse events when used in combination with other medications for opioid use disorder (OUD). It is not expected to cause opioid withdrawal and may be safe when used in combination with other medications. FOR FURTHER INFORMATION, PLEASE CONTACT: CounterX Therapeutics Jacques Bouchy Chief Business Officer 206.486.4755 [email protected] SOURCE CounterX Therapeutics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Vaccine

23 Oct 2025

·www.fiercepharma.com

FDA cites Nephron again for ongoing issues the generics manufacturer has failed to resolve

Generics contract manufacturer Nephron Pharmaceuticals is in hot water again with the FDA after an August inspection of its facility in South Carolina turned up several issues that have been ongoing for the last few years. Three years ago, the FDA found so many violations at a Nephron Pharmaceuticals manufacturing facility that the U.S. regulator admitted in a warning letter the issues were so numerous they couldn’t all be documented.Fast-forward to this year, and the plant in West Columbia, South Carolina, is still running afoul of the FDA. In a recent Form 483 report, the agency cited several problems that were evident in an August inspection of the facility. Most of the observations were repeat issues identified in Nephron's previous interactions with the agency.Most notably, the report identified a lack of procedures to prevent contamination of manufactured products. The procedures are “not established and written,” the FDA said.“These repeated and systemic lapses demonstrate that your firm has not implemented or enforced adequate aseptic practices to maintain sterility assurance of drug products,” the inspectors wrote.The inspectors identified a laundry list of sterility issues, including operators failing to wash their hands or to clean IV bags. Trash removal was conducted while filling operations were in progress. Doors to manufacturing rooms were left open during aseptic operations. Sanitizing wipes that are designed for single use were reused after being left on shelves. The report also specified a variety of airflow problems.The regulator added that the overall lack of procedures to prevent microbial contamination was a “repeated observation” from inspections performed in 2023 and 2024.The company did not immediately respond to a request for comment.Nephron is a privately owned contract manufacturer of generic respiratory medications. It also serves as a 503B outsourcing facility, producing medications for U.S. hospitals that are in shortage. The company specializes in blow-fill-seal production. The technology is designed to allow medications to be formed, filled and sealed in a continuous process without human intervention in a sterile, closed area. In its write-up, the FDA further noted Nephron’s system for monitoring environmental conditions was lacking and that the company had not established an environmental monitoring program. This also was a repeated observation from a 2024 report of an inspection of the plant.The inspectors also found deficiencies in alarm management, with employees disregarding alerts designed to maintain aseptic conditions. This also was a repeated observation from a 2024 inspection.“These deficiencies in alarm management and oversight create an unacceptable risk of microbial ingress and contamination of sterile products.” the FDA wrote.Additionally, Nephron failed to establish adequate written procedures for production and process controls designed to assure drug products meet strength, purity and quality specifications, according to the FDA.Nephron has previously run afoul of the FDA. In 2013, the company was cited for its marketing of an over-the-counter asthma medication. Two years later, the company recalled 80,000 cartons of the drug over discoloration issues. In 2022, Nephron came under intense scrutiny when it recalled more than 2 million drug doses—covering a wide variety of products including sodium bicarbonate injections, ephedrine injections and fentanyl citrate bags—because of sterility concerns. In an exhaustive warning letter that year, the FDA identified several of the same issues raised in the most recent report.

23 Oct 2025

·orexo.com

Orexo Q3 2025 Interim Report

Unlocking the potential of the AmorphOX® technology Q3 2025 highlights › Total net revenues of SEK 118.7 m (136.5) › EBITDA of SEK -9.8 m (-0.7), including a negative impact from costs associated with LTIP programs of SEK -12.9 m › Net earnings of SEK -29.8 m (-41.9) › US Commercial segment net revenues of SEK 113.9 m (131.0), in local currency USD 12.0 m (12.6) › Cash flow from operating activities of SEK -10.3 m (-13.4), cash and cash equivalents of SEK 105.6 m (114.9) › Earnings per share before dilution and after dilution amounted to SEK -0.86 (-1.21) › Positive in-vivo data showed for a powder-based intranasal GLP-1 agonist medication supported by the AmorphOX® technology › The subsidiary, Orexo US Inc., awarded approx. SEK 75 m (USD 8 m) by BARDA for the development of OX390, an intranasal rescue medication for adulterated overdoses. Pending milestones and deliverables the award is valued up to approx. SEK 480 m (USD 50.9 m). › 2025 financial outlook reiterated. Important events after the end of the period › No important events after the end of the period. SEK m unless otherwise stated 2025 Jul-Sep2024 Jul-Sep2025 Jan-Sep2024 Jan-Sep2024 Jan-DecNet revenues118.7136.5383.2429.7590.0Cost of goods sold-7.1-20.1-36.3-49.7-72.1Operating expenses-132.7-138.1-394.7-422.3-658.2EBIT-21.1-21.7-47.8-42.2-140.3EBIT margin %neg.neg.neg.neg.neg.EBITDA-9.8-0.7-14.020.248.9Earnings per share, before dilution, SEK-0.86-1.21-2.47-2.51-5.89Earnings per share, after dilution, SEK-0.86-1.21-2.47-2.51-5.89Cash flow from operating activities-10.3-13.421.9-38.8-32.6Cash and cash equivalents105.6114.9105.6114.9123.3 CEO Comments in brief Orexo has a strong track record of turning platform technologies into approved medicines. Our sublingual platform enabled multiple FDA-approved products, including Zubsolv® and Abstral®, that generated significant revenues for the company. Building on that success, we are now concentrating resources on the AmorphOX® platform, our next-generation formulation engine designed to unlock proprietary products and expand our pipeline. During the quarter, we reached two key milestones that reinforce the scalability of the AmorphOX platform. The breakthrough with the GLP-1 agonist and the BARDA¹ financing secured for the OX390 project both strengthen the platform and its future potential. I am encouraged by the enthusiasm these developments have generated among our key stakeholders, and by the growing recognition of AmorphOX’s long-term value. From a financial perspective, EBITDA was negative, however, we would have reported positive EBITDA for the quarter absent provisions for social security fees related to the long-term incentive program following the positive share price development in the quarter. Zubsolv demand is stable, but top line sales were impacted by foreign exchange rate headwinds and significantly lower inventory levels with the wholesalers. We expect Zubsolv sales to improve in the fourth quarter consistently with historical seasonal patterns and we maintain our full-year guidance. Uppsala, Sweden, October 23, 2025 Nikolaj Sørensen President and CEO Contact persons interim report Nikolaj Sørensen, President and CEO Fredrik Järrsten, EVP and CFO Lena Wange, IR & Communications Director Tel: +46 18 780 88 00, +1 855 982 7658, E-mail: ir@orexo.com. Presentation On October 23, at 2 pm CEST analysts, investors and media are invited to attend a presentation, incl. a Q&A. Participants may access the event via live webcast or teleconference through the following link: https://investorcaller.com/events/orexo/orexo-q3-report-2025 Prior to the call, presentation material will be available on the website under Investors/Rapport archive.

Financial Statement

100 Deals associated with Fentanyl Citrate

External Link

KEGG	Wiki	ATC	Drug Bank
D01399	Fentanyl Citrate	N02AB03 N01AH01	DB00813

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Pain	United States	Adalvo Ltd.	16 Jul 2009
Breakthrough Pain	European Union	Teva Pharmaceuticals Europe BV	04 Apr 2008
Breakthrough Pain	Iceland	Teva Pharmaceuticals Europe BV	04 Apr 2008
Breakthrough Pain	Liechtenstein	Teva Pharmaceuticals Europe BV	04 Apr 2008
Breakthrough Pain	Norway	Teva Pharmaceuticals Europe BV	04 Apr 2008
Cancer Pain	United States	Cephalon, Inc.	04 Nov 1998
Hyperemesis Gravidarum	China	Yichang Humanwell Pharmaceuticals Co., Ltd.	01 Jan 1981
Anesthesia	United States	Rising Pharmaceuticals, Inc.	19 Feb 1968

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Head and Neck Neoplasms	Phase 3	Italy	L. Molteni & C. dei F.lli Alitti Società di Esercizio SpA	01 Sep 2014
Respiratory Insufficiency	Phase 3	-	BioDelivery Sciences International, Inc.	01 Jun 2008
Chronic Pain	Phase 3	United States	Cephalon, Inc.	01 Dec 2006
Complex Regional Pain Syndromes	Phase 3	United States	Cephalon, Inc.	01 Sep 2005
Low Back Pain	Phase 3	United States	Cephalon, Inc.	01 Sep 2005
Neuralgia	Phase 3	United States	Cephalon, Inc.	01 Sep 2005
Neuralgia, Postherpetic	Phase 3	United States	Cephalon, Inc.	01 Sep 2005
Neoplasms	Phase 3	-	Cephalon, Inc.	01 Jun 2004
Dyspnea, Paroxysmal	Phase 2	Germany	Teva Branded Pharmaceutical Products R&D, Inc.	01 Mar 2013
Lung Cancer	Phase 2	Germany	Teva Branded Pharmaceutical Products R&D, Inc.	01 Mar 2013

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04230681 (CTgov)	Early Phase 1	Sleep Apnea, Obstructive \| Tonsillitis	189	Hydromorphone (Hydromorphone)	dqenecljpf = mwykgxrcxf wnmbmjtqbn (fxemerbtrv, zrakcxngmy - jlblboofsp) View more	-	18 Dec 2024
				Fentanyl (Fentanyl)	dqenecljpf = ankotapnir wnmbmjtqbn (fxemerbtrv, nszygcycyn - ccjioxtqwi) View more
WCLC2024 Manual	Phase 3	Sedation	84	Midazolam with Fentanyl	ytauiwzpmi(akkgwmzlgv) = spheazopdi nhzsessybl (sndhtsjxuq ) View more	Positive	07 Sep 2024
				Midazolam with Placebo	ytauiwzpmi(akkgwmzlgv) = zhqqixaiyq nhzsessybl (sndhtsjxuq ) View more
NCT03435003 (CTgov)	Phase 4	Postoperative Nausea and Vomiting \| Vomiting	83	dexmedetomidine+Total intravenous anesthesia+Fentanyl+scopolamine transdermal+Compazine+sugammadex+Reglan+Propofol+Dexamethasone+Ondansetron+Aprepitant 80 mg Oral Capsule (Intervention Arm)	trjecvhafm = bxsjqlvipe seyulfbyfe (tgtshmugmz, nztvnqglba - vwbnybnhat) View more	-	14 Feb 2024
				Compazine+sugammadex+Reglan+Sevoflurane+Dexamethasone+desflurane+Ondansetron (Control Arm)	trjecvhafm = aepngsbjqd seyulfbyfe (tgtshmugmz, jisohxhfck - tensqqryxu) View more
NCT03115151 (CTgov)	Phase 4	Pain	46	Fentanyl+Bupivacaine (Patient-Controlled Epidural Analgesia)	wichuixirx(dhfweqtvuz) = bgftgnzles bldckxkfei (nzeohzfjkb, 24.69) View more	-	26 Oct 2023
				Hydromorphone (Intravenous Patient-controlled Analgesia)	wichuixirx(dhfweqtvuz) = tbwaiprtsw bldckxkfei (nzeohzfjkb, 25.41) View more
NCT01488045 (CTgov)	Not Applicable	Diverticulosis, Colonic \| Rectal Cancer \| Colonic Cancer	289	Propofol (Propofol Intervention)	pofvyunftp(hdalhyuusb) = jdyatiojgd qpvdevkqmx (uhifnuerbu, 12.8) View more	-	23 May 2023
				Fentanyl+Midazolam (Midazolam/Fentanyl Intervention)	pofvyunftp(hdalhyuusb) = shfnqmqnmi qpvdevkqmx (uhifnuerbu, 28.3) View more
NCT01362998 (CTgov)	Not Applicable	Analgesia	2	morphine (Preservative Free Morphine)	zgrjyjqudh(ewucryogxn) = bvlobcbzgp ymqvfjyeav (yewcrlozkr, jklnefjyjo - zbqdanqvpk) View more	-	14 Nov 2022
				Fentanyl (Fentanyl Infusion)	ttvcgjuscm = fmdfcwdyra yxktrekrpb (msqxctghct, ttmhfnfctp - bxdmxasdbw) View more
NCT03882788 (NDO, CTgov)	Not Applicable	Heart Defects, Congenital \| Maternal anesthesia and analgesia affecting fetus or newborn \| Neurodevelopmental Disorders	153	Fentanyl (Narcotic Based Anesthesia)	tnjcocvjmc(tkzxfnxesp) = tefjdzmbzx vzlvoryxgl (eyxfhmfxvk, 10) View more	-	09 May 2022
				Fentanyl+Isoflurane (Volatile Anesthesia)	tnjcocvjmc(tkzxfnxesp) = xfcvpnynmu vzlvoryxgl (eyxfhmfxvk, 15) View more
NCT03938857 (DOSE, CTgov)	Phase 1	Critical Illness \| Mechanical ventilation complication	30	Fentanyl (Fen. SOC+Saline Placebo (Bolus+Infusion))	tkfslbjtye(clqwvpwbsd) = wkhavcluop gtdwppmadr (ajvyxvxpvr, 2.15) View more	-	05 Nov 2021
				dexmedetomidine+Fentanyl (Fen. SOC+Dex.(.5mcg/kg + .25mcg/kg/hr))	tkfslbjtye(clqwvpwbsd) = gwccgmgcdf gtdwppmadr (ajvyxvxpvr, 1.53) View more
NCT03435692 (CTgov)	Not Applicable	Pain, Postoperative	42	ropivacaine (Lumbar Epidural Catheter (< 6 Years Old))	qvimmimeph(khfbfbtmut) = tosfzmhmpx ofrjwzgaje (sbrsuxtzyw, 0.5) View more	-	02 Nov 2021
				ropivacaine (Lumbar Plexus Catheter (< 6 Years Old))	qvimmimeph(khfbfbtmut) = pnuyefafln ofrjwzgaje (sbrsuxtzyw, 0.8) View more
NCT02747875 (CV_RCT_M_F, CTgov)	Not Applicable	Pain, Postoperative	26	Fentanyl (Control - Fentanyl)	lbgjjpjarm(uhdscyjsdq) = hevpqpdiyv mzrcalbvpw (bflkzxkzkd, 0.21) View more	-	01 Jun 2021
				Methadone (Treatment - Methadone)	lbgjjpjarm(uhdscyjsdq) = lyrpsyvbvm mzrcalbvpw (bflkzxkzkd, 0.24) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis